Pfizer Inc said it has received a complete response letter from the US FDA asking for additional information on the company's application for lasofoxifene. The investigational compound is currently under review for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.
The details can be read here.
No comments:
Post a Comment